Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063238 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT07063238 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 42 participants.
The verdict
NCT07063238, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may have trouble following a PrEP plan because it involves either taking medicine everyday by mouth or getting injections (shots) often. MK-8527 is a study medicine designed to prevent HIV-1 infection. MK-8527 is different from standard (usual) PrEP because it is taken once a month, by mouth, as a tablet. The goal of this study is to learn if taking a higher-than-normal dose of MK-8527 increases the QT interval (a measure of heart rhythm) by a certain amount.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG MK-8527
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07063238
The ClinicalTrials.gov registry entry for NCT07063238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07063238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07063238 about?
NCT07063238 is a clinical study titled "A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)". Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may...
What is the current status of trial NCT07063238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-08-12. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT07063238?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), MK-8527 (DRUG).
Who is sponsoring clinical trial NCT07063238?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.